Researchers Develop Method to Predict When Doctors Will Reject Clinical AI System Responses
Researchers at an academic medical center built a machine learning classifier that predicts, before an LLM generates a response, whether a clinician will reject that response, achieving an AUROC of 0.719 over 4.5 months of prospective evaluation. The system is embedded within electronic health records and uses deployment-specific context—such as provider type, department, and which language model is in use—alongside query content to make predictions. The work highlights a path toward targeted guardrails and abstention mechanisms that could improve the real-world safety and utility of clinical AI systems.
A study submitted to arXiv proposes a deployment-centered evaluation framework for large language models integrated into clinical electronic health record (EHR) systems, arguing that standard static benchmarks fail to capture real-world user acceptance. The researchers trained a pre-response classifier—one that operates before the LLM generates an answer—to estimate the probability that a clinician will reject the system's output for a given query. Evaluated prospectively over 4.5 months of sparse but deployment-authentic user feedback, the classifier achieved an AUROC of 0.719. A key finding is that incorporating deployment-specific context (provider type, department name, and the specific LLM used) meaningfully improves predictive performance beyond using query content alone. The authors analyzed two downstream applications of such predictions: triggering guardrails to intercept likely-rejected queries and enabling the system to abstain from answering when rejection risk is high. The study frames itself as an empirical case study demonstrating feasibility rather than a production-ready solution, and the authors suggest the approach opens the door to more targeted, context-aware safety mechanisms in clinical AI.
What's missing
It is unclear how 'rejection' was operationalized from sparse user feedback, what the false-positive and false-negative costs are in clinical practice, or whether the classifier generalizes beyond the single academic medical center studied. The authors acknowledge the case-study nature of the work but do not discuss potential automation bias risks if clinicians over-rely on guardrail decisions.
What different sources said
- arXiv cs.AICenter
Deployment-Centered Evaluation: Predicting Query-Level Rejection Risk in a Clinical LLM System
Related
Gut Bacteria Enzyme Found to Break Down Heat-Processed Food Compounds, Producing Novel Biogenic Amines
Researchers have discovered that an enzyme in common gut bacteria can degrade N-epsilon-carboxymethyllysine (CML), a compound formed during thermal food processing, producing previously unknown biogenic amines. The enzyme, ornithine decarboxylase SpeC from enterobacteria, acts on CML and related modified lysine derivatives through a low-level 'underground' catalytic activity. This finding suggests a previously unrecognized communication axis between thermally processed dietary compounds and gut microbial physiology, with potential implications for host health.
Full-Length Gene Sequencing Reveals Two Distinct Bacterial Communities in Black-Legged Ticks Expanding Into Canada
Researchers used Oxford Nanopore full-length 16S rRNA gene sequencing to characterize the microbiome of Ixodes scapularis black-legged ticks collected in Nova Scotia, Canada, distinguishing between tick-adapted bacteria and environmentally acquired bacteria. The study comes as I. scapularis — the primary vector of Lyme disease — is rapidly expanding northward into Canada due to climate change. The findings suggest that environmentally derived bacteria in tick microbiomes are not mere contamination, which has implications for how tick microbiome data is collected and interpreted across surveillance studies.
Study Identifies Metabolic Link Between Cell Envelope Stress and Biofilm Formation in Bacteria
Researchers have discovered that the metabolite acetyl-CoA directly inhibits enzymes that degrade the bacterial signaling molecule c-di-GMP, connecting cell envelope biosynthesis stress to biofilm formation in Pseudomonas aeruginosa. The study found that sub-inhibitory concentrations of antibiotics targeting early peptidoglycan biosynthesis — but not other antibiotic classes — elevate c-di-GMP levels by reducing phosphodiesterase activity, with acetyl-CoA competing for the enzyme active site. Because the relevant enzyme domain is broadly conserved across bacterial species, this checkpoint mechanism may be widespread and could have implications for understanding antibiotic-induced biofilm responses.